Logo image of CRIN.DE

UNICREDIT SPA (CRIN.DE) Stock Fundamental Analysis

Europe - FRA:CRIN - IT0005239360 - Common Stock

63.81 EUR
+0.35 (+0.55%)
Last: 10/3/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CRIN. CRIN was compared to 97 industry peers in the Banks industry. Both the profitability and financial health of CRIN have multiple concerns. CRIN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

CRIN had positive earnings in the past year.
In the past year CRIN has reported a negative cash flow from operations.
CRIN had positive earnings in 4 of the past 5 years.
In multiple years CRIN reported negative operating cash flow during the last 5 years.
CRIN.DE Yearly Net Income VS EBIT VS OCF VS FCFCRIN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B -20B 40B -40B 60B 80B

1.2 Ratios

CRIN has a better Return On Assets (1.13%) than 75.26% of its industry peers.
CRIN has a better Return On Equity (14.29%) than 79.38% of its industry peers.
Industry RankSector Rank
ROA 1.13%
ROE 14.29%
ROIC N/A
ROA(3y)1.06%
ROA(5y)0.61%
ROE(3y)13.49%
ROE(5y)7.61%
ROIC(3y)N/A
ROIC(5y)N/A
CRIN.DE Yearly ROA, ROE, ROICCRIN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

Looking at the Profit Margin, with a value of 32.18%, CRIN belongs to the top of the industry, outperforming 82.47% of the companies in the same industry.
In the last couple of years the Profit Margin of CRIN has grown nicely.
The Operating Margin and Gross Margin are not available for CRIN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 32.18%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y84.53%
PM growth 5Y19.61%
GM growth 3YN/A
GM growth 5YN/A
CRIN.DE Yearly Profit, Operating, Gross MarginsCRIN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1

2. Health

2.1 Basic Checks

CRIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRIN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CRIN has been reduced compared to 5 years ago.
The debt/assets ratio for CRIN is higher compared to a year ago.
CRIN.DE Yearly Shares OutstandingCRIN.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
CRIN.DE Yearly Total Debt VS Total AssetsCRIN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200B 400B 600B 800B

2.2 Solvency

CRIN has a Debt/Equity ratio of 3.14. This is a high value indicating a heavy dependency on external financing.
CRIN has a worse Debt to Equity ratio (3.14) than 70.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.14
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC5.6%
CRIN.DE Yearly LT Debt VS Equity VS FCFCRIN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50B 100B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CRIN.DE Yearly Current Assets VS Current LiabilitesCRIN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

4

3. Growth

3.1 Past

CRIN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.41%, which is quite good.
CRIN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.66% yearly.
The Revenue has been growing slightly by 5.45% in the past year.
Measured over the past years, CRIN shows a small growth in Revenue. The Revenue has been growing by 4.09% on average per year.
EPS 1Y (TTM)18.41%
EPS 3Y49.15%
EPS 5Y18.66%
EPS Q2Q%34.16%
Revenue 1Y (TTM)5.45%
Revenue growth 3Y0.8%
Revenue growth 5Y4.09%
Sales Q2Q%-3.18%

3.2 Future

CRIN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.62% yearly.
The Revenue is expected to grow by 1.05% on average over the next years.
EPS Next Y18%
EPS Next 2Y11.74%
EPS Next 3Y11.49%
EPS Next 5Y6.62%
Revenue Next Year-0.14%
Revenue Next 2Y0.92%
Revenue Next 3Y1.54%
Revenue Next 5Y1.05%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRIN.DE Yearly Revenue VS EstimatesCRIN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 10B 20B 30B
CRIN.DE Yearly EPS VS EstimatesCRIN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 5 -5

5

4. Valuation

4.1 Price/Earnings Ratio

CRIN is valuated reasonably with a Price/Earnings ratio of 9.73.
Compared to the rest of the industry, the Price/Earnings ratio of CRIN is on the same level as its industry peers.
CRIN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.86.
Based on the Price/Forward Earnings ratio of 8.90, the valuation of CRIN can be described as reasonable.
Based on the Price/Forward Earnings ratio, CRIN is valued a bit cheaper than the industry average as 79.38% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.32. CRIN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.73
Fwd PE 8.9
CRIN.DE Price Earnings VS Forward Price EarningsCRIN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRIN.DE Per share dataCRIN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

CRIN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.54
PEG (5Y)0.52
EPS Next 2Y11.74%
EPS Next 3Y11.49%

4

5. Dividend

5.1 Amount

CRIN has a Yearly Dividend Yield of 3.74%.
Compared to an average industry Dividend Yield of 5.02, CRIN is paying slightly less dividend.
Compared to an average S&P500 Dividend Yield of 2.41, CRIN pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.74%

5.2 History

The dividend of CRIN is nicely growing with an annual growth rate of 38.95%!
Dividend Growth(5Y)38.95%
Div Incr Years3
Div Non Decr Years3
CRIN.DE Yearly Dividends per shareCRIN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

42.97% of the earnings are spent on dividend by CRIN. This is a bit on the high side, but may be sustainable.
The dividend of CRIN is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP42.97%
EPS Next 2Y11.74%
EPS Next 3Y11.49%
CRIN.DE Yearly Income VS Free CF VS DividendCRIN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B -20B 40B -40B 60B 80B
CRIN.DE Dividend Payout.CRIN.DE Dividend Payout, showing the Payout Ratio.CRIN.DE Dividend Payout.PayoutRetained Earnings

UNICREDIT SPA

FRA:CRIN (10/3/2025, 7:00:00 PM)

63.81

+0.35 (+0.55%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)07-23 2025-07-23/bmo
Earnings (Next)10-27 2025-10-27
Inst Owners50.66%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap99.40B
Analysts77.39
Price Target68.96 (8.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.74%
Yearly Dividend3.03
Dividend Growth(5Y)38.95%
DP42.97%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.08%
Min EPS beat(2)13.37%
Max EPS beat(2)34.79%
EPS beat(4)3
Avg EPS beat(4)10.13%
Min EPS beat(4)-15.25%
Max EPS beat(4)34.79%
EPS beat(8)7
Avg EPS beat(8)16.67%
EPS beat(12)11
Avg EPS beat(12)24.22%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.36%
Min Revenue beat(2)-1.87%
Max Revenue beat(2)6.59%
Revenue beat(4)3
Avg Revenue beat(4)2.05%
Min Revenue beat(4)-1.87%
Max Revenue beat(4)6.59%
Revenue beat(8)7
Avg Revenue beat(8)2.91%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.46%
PT rev (3m)15.37%
EPS NQ rev (1m)0.45%
EPS NQ rev (3m)4.88%
EPS NY rev (1m)0.06%
EPS NY rev (3m)8.44%
Revenue NQ rev (1m)1.26%
Revenue NQ rev (3m)4.38%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)2.21%
Valuation
Industry RankSector Rank
PE 9.73
Fwd PE 8.9
P/S 3.29
P/FCF N/A
P/OCF N/A
P/B 1.46
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)6.56
EY10.28%
EPS(NY)7.17
Fwd EY11.23%
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS19.39
BVpS43.67
TBVpS41.57
PEG (NY)0.54
PEG (5Y)0.52
Profitability
Industry RankSector Rank
ROA 1.13%
ROE 14.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 32.18%
GM N/A
FCFM N/A
ROA(3y)1.06%
ROA(5y)0.61%
ROE(3y)13.49%
ROE(5y)7.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y84.53%
PM growth 5Y19.61%
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 3.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.71%
Cap/Sales 3.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score2
WACC5.6%
ROIC/WACCN/A
Cap/Depr(3y)97.97%
Cap/Depr(5y)95.45%
Cap/Sales(3y)4.61%
Cap/Sales(5y)5.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3Y49.15%
EPS 5Y18.66%
EPS Q2Q%34.16%
EPS Next Y18%
EPS Next 2Y11.74%
EPS Next 3Y11.49%
EPS Next 5Y6.62%
Revenue 1Y (TTM)5.45%
Revenue growth 3Y0.8%
Revenue growth 5Y4.09%
Sales Q2Q%-3.18%
Revenue Next Year-0.14%
Revenue Next 2Y0.92%
Revenue Next 3Y1.54%
Revenue Next 5Y1.05%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y94.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.9%
OCF growth 3YN/A
OCF growth 5YN/A